Symmetry Medical (SMA) Given Media Impact Score of 0.20

News articles about Symmetry Medical (NYSE:SMA) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Symmetry Medical earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the healthcare company an impact score of 43.9662743217684 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

ILLEGAL ACTIVITY WARNING: “Symmetry Medical (SMA) Given Media Impact Score of 0.20” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/12/22/symmetry-medical-sma-given-media-impact-score-of-0-20.html.

About Symmetry Medical

Symmetry Medical Inc (Symmetry) is a medical device solutions company, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company designs, develops and offers worldwide production and supply chain capabilities for these products to customers in the orthopedic industry, and other medical device markets (including but not limited to arthroscopy, dental, laparoscopy, osteobiologic, and endoscopy segments).

Insider Buying and Selling by Quarter for Symmetry Medical (NYSE:SMA)

Receive News & Ratings for Symmetry Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symmetry Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit